(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
06 July 2023 (06.07.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/126170 A1

(51) International Patent Classification:
G16H 50/20 (2018.01) *G16H 10/20* (2018.01)
G16H 50/30 (2018.01) *G06N 20/00* (2019.01)
G16H 50/50 (2018.01)

(21) International Application Number:
PCT/EP2022/085684

(22) International Filing Date:
13 December 2022 (13.12.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2119104.4 29 December 2021 (29.12.2021) GB
2211324.5 03 August 2022 (03.08.2022) GB

(71) Applicant: **WISTA LABORATORIES LTD.** [SG/SG]; 25 Bukit Batok Crescent, The Elitist #6-13, Singapore 658066 (SG).

(72) Inventors: **AGARWAL, Anish**; 48 Clifton Road, Newton, Massachusetts 02459 (US). **MISRA, Vishal**; 107 W 89th St., Apt GA, New York, New York 10024 (US). **SCHELTER, Bjoern**; TauRx Therapeutics Ltd, 395 King Street, Aberdeen Aberdeenshire AB24 5RP (GB). **SHAH, Devavrat**; 703 Chestnut Street, Waban, Massachusetts 02468 (US). **SHEN, Dennis**; 3695 Provincetown Av, Irvine, California 92606 (US). **SHIELLS, Helen**; TauRx Therapeutics Ltd, 395 King Street, Aberdeen Aberdeenshire AB24 5RP (GB). **WISCHIK, Claude Michel**; TauRx Therapeutics Ltd., 395 King Street, Aberdeen Aberdeenshire AB24 5RP (GB).

(74) Agent: **MEWBURN ELLIS LLP**; Aurora Building, Counterslip, Bristol BS1 6BX (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,

(54) Title: METHOD OF PREDICTING ADAS-COG SCORE



Fig. 6

(57) Abstract: A method for predicting a patient or patient cohort's cognition score on the Alzheimer's Disease Assessment Scale – cognitive subscale (ADAS-Cog). The method comprises obtaining data relating to a plurality of patients or patient cohorts, the data including information relating to the longitudinal trajectories of the plurality of patients', or patient cohorts', ADAS-Cog score over time, each patient or patient cohort having undergone a treatment plan selected from a plurality of treatment plans; encoding the data into a tensor across patients or patient cohorts, time and treatment plan; generating a synthetic model of a target patient or target patient cohort using a machine learning process and the tensor; and predicting an ADAS-Cog score of the target patient or target patient cohort under a target treatment plan selected from the plurality of treatment plans, using the synthetic model.

WO 2023/126170 A1

[Continued on next page]

LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*